New triple-drug combo aims to keep advanced breast cancer in check
NCT ID NCT07470203
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding pyrotinib to two standard drugs (trastuzumab and pertuzumab) can help control HER2-positive advanced breast cancer longer. About 42 adults with advanced disease will receive this combination as maintenance therapy after initial treatment. The main goal is to see how long the cancer stays under control without growing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?